Cancer anti-sickness drug offers hope for hallucinations in Parkinson’s
Monday 26 October 2020 - A world-first double-blind clinical trial, will investigate if a powerful drug used to treat nausea in...
Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd.
Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
Parkinson's UK meets with UK regulatory agency to discuss upcoming repurposing trial
This week key colleagues from Parkinson's UK met with the UK Medicines and Healthcare products Regulatory Agency (MHRA) along with...
Promising drug could treat debilitating movement problems in people with Parkinson’s
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may hav
Investment in NRG Therapeutics to generate molecules targeting mitochondrial dysfunction on track
Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with NRG Therapeutics Ltd...
Parkinson's Foundation partners with Parkinson's UK
Parkinson's Foundation grants £200,000 to Parkinson's UK to invest in the Parkinson's Virtual Biotech. Each year, Parkinson's UK, their...